Apogee Therapeutics, Inc. (APGE) SEC Filings — 2025
12 SEC filings for Apogee Therapeutics, Inc. (APGE) in 2025.
Filings
- Apogee's R&D Surge Drives 62% Net Loss Increase to $186M — 10-Q · Nov 10, 2025
- Apogee Therapeutics Files 8-K for Material Definitive Agreement — 8-K · Oct 10, 2025
- Apogee's Q2 Net Loss Widens to $55.2M Amid R&D Surge — 10-Q · Aug 11, 2025
- Apogee Therapeutics Files 8-K — 8-K · Jul 7, 2025
- Apogee Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 23, 2025
- Apogee Therapeutics Files 8-K on Financials and Operations — 8-K · May 12, 2025
- Apogee Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025
- Apogee Therapeutics DEF 14A: Executive Compensation Details — DEF 14A · Apr 29, 2025
- Apogee Therapeutics Enters Material Definitive Agreement — 8-K · Mar 11, 2025
- Apogee Therapeutics Files 8-K: Operations & Financials — 8-K · Mar 3, 2025
- Apogee Therapeutics Files 2024 10-K — 10-K · Mar 3, 2025
- Apogee Therapeutics Files 8-K — 8-K · Feb 3, 2025